Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $52.65

Janux Therapeutics, Inc. (NASDAQ:JANX) shares gapped down before the market opened on Monday . The stock had previously closed at $52.65, but opened at $51.05. Janux Therapeutics shares last traded at $50.67, with a volume of 128,178 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on JANX shares. BTIG Research started coverage on Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price target for the company. Jonestrading began coverage on Janux Therapeutics in a research report on Tuesday. They set a “buy” rating and a $70.00 target price on the stock. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Cantor Fitzgerald initiated coverage on shares of Janux Therapeutics in a report on Wednesday, March 20th. They set an “overweight” rating and a $100.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and issued a $53.00 target price on shares of Janux Therapeutics in a report on Monday, March 11th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $61.33.

Janux Therapeutics Price Performance

The company’s fifty day moving average is $32.84 and its 200 day moving average is $17.39.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Friday, March 8th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The business had revenue of $2.46 million for the quarter, compared to the consensus estimate of $0.98 million. As a group, equities analysts expect that Janux Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of JANX. Nisa Investment Advisors LLC lifted its position in Janux Therapeutics by 10,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after acquiring an additional 2,685 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Janux Therapeutics by 149.4% in the first quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock valued at $40,000 after acquiring an additional 2,003 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Janux Therapeutics during the fourth quarter worth about $57,000. Barclays PLC lifted its holdings in Janux Therapeutics by 533.0% during the 4th quarter. Barclays PLC now owns 4,608 shares of the company’s stock worth $61,000 after buying an additional 3,880 shares during the last quarter. Finally, Citigroup Inc. grew its position in shares of Janux Therapeutics by 935.2% in the 2nd quarter. Citigroup Inc. now owns 5,787 shares of the company’s stock worth $69,000 after acquiring an additional 5,228 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.